Skip to main content
. Author manuscript; available in PMC: 2018 Feb 20.
Published in final edited form as: N Engl J Med. 2017 Dec 10;378(4):331–344. doi: 10.1056/NEJMoa1708984

Figure 1. Modified Progression-free Survival in the Intention-to-Treat Population.

Figure 1

Panel A shows Kaplan–Meier estimates of modified progression-free survival, by treatment group, according to the independent review committee. The hazard ratio for treatment with A+AVD versus ABVD and the 95% confidence intervals (CIs) were based on a stratified Cox proportional-hazards regression model, with treatment as the explanatory variable. Stratification factors included region and International Prognostic Score risk group at baseline. Panel B shows Kaplan–Meier estimates of modified progression-free survival, by treatment group, according to investigators. In Panels A and B, circles indicate censored data. A+AVD denotes brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine, and ABVD doxorubicin, bleomycin, vinblastine, and dacarbazine.